HLA-A*02:01&B2M&Survivin (LMLGEFLKL) Tetramer, His & Avi, Human
HLA-A*02:01&B2M&Survivin (LMLGEFLKL) Tetramer, His & Avi, Human

Immobilized HLA-A*02:01&B2M&Survivin (LMLGEFLKL) Tetramer, His & Avi, Human, His Tag at 0.5 μg/ml (100 μl/well) on the plate. Dose response curve for Anti-B2M Antibody, mFc Tag with the EC50 of 9.5 ng/ml determined by ELISA.

HLA-A*02:01&B2M&Survivin (LMLGEFLKL) Tetramer, His & Avi, Human

The purity of HLA-A*02:01&B2M&Survivin (LMLGEFLKL) Tetramer, His & Avi, Human is greater than 95% as determined by SEC-HPLC.

HLA-A*02:01&B2M&Survivin (LMLGEFLKL) Tetramer, His & Avi, Human

HLA-A*02:01&B2M&Survivin (LMLGEFLKL) Tetramer, His & Avi, Human on Bis-Tris PAGE under Non reducing (N) condition. The purity is greater than 95%.

HLA-A*02:01&B2M&Survivin (LMLGEFLKL) Tetramer, His & Avi, Human

Survivin (also known as BIRC5) is an evolutionarily conserved eukaryotic protein that is essential for cell division and can inhibit cell death. Normally it is only expressed in actively proliferating cells, but is upregulated in most, if not all cancers; consequently, it has received significant attention as a potential oncotherapeutic target.
Z06595
¥208,928.00

Ask us a question
Product Introduction
Species Human
Protein Construction
HLA-A*02:01&B2M&Survivin (LMLGEFLKL) Tetramer[Gly25-Thr305(HLA-A*02:01), Ile21-Met119(B2M) and LMLGEFLKL peptide]
Accession # A0A140T913(HLA-A*02:01)&P61769(B2M)&LMLGEFLKL		 His Avi
N-term C-term
Purity > 95% as determined by Bis­Tris PAGE
Endotoxin Level Less than 1EU per μg by the LAL method.
Biological Activity Measured by its binding ability in a functional ELISA.Test result was comparable to standard batch.
Expression System HEK293
Theoretical Molecular Weight 258 kDa
Apparent Molecular Weight Due to glycosylation, the protein migrates to 260-265 kDa under Non reducing (N) condition based on Bis-Tris PAGE result.
Formulation Lyophilized from 0.22μm filtered solution in PBS (pH 7.4).
Reconstitution Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
Storage & Stability Upon receiving, the product remains stable for 6 months at -20℃ or below. Upon reconstitution, the product should be stable for 3 months at -80℃. Avoid repeated freeze-thaw cycles.

Examples
  • HLA-A*02:01&B2M&Survivin (LMLGEFLKL) Tetramer, His & Avi, Human
    • HLA-A*02:01&B2M&Survivin (LMLGEFLKL) Tetramer, His & Avi, Human

    Immobilized HLA-A*02:01&B2M&Survivin (LMLGEFLKL) Tetramer, His & Avi, Human, His Tag at 0.5 μg/ml (100 μl/well) on the plate. Dose response curve for Anti-B2M Antibody, mFc Tag with the EC50 of 9.5 ng/ml determined by ELISA.

  • HLA-A*02:01&B2M&Survivin (LMLGEFLKL) Tetramer, His & Avi, Human
    • HLA-A*02:01&B2M&Survivin (LMLGEFLKL) Tetramer, His & Avi, Human

    The purity of HLA-A*02:01&B2M&Survivin (LMLGEFLKL) Tetramer, His & Avi, Human is greater than 95% as determined by SEC-HPLC.

  • HLA-A*02:01&B2M&Survivin (LMLGEFLKL) Tetramer, His & Avi, Human
    • HLA-A*02:01&B2M&Survivin (LMLGEFLKL) Tetramer, His & Avi, Human

    HLA-A*02:01&B2M&Survivin (LMLGEFLKL) Tetramer, His & Avi, Human on Bis-Tris PAGE under Non reducing (N) condition. The purity is greater than 95%.


Background
Target Background Survivin (also known as BIRC5) is an evolutionarily conserved eukaryotic protein that is essential for cell division and can inhibit cell death. Normally it is only expressed in actively proliferating cells, but is upregulated in most, if not all cancers; consequently, it has received significant attention as a potential oncotherapeutic target.
Synonyms Survivin; MHC; MHC I; BIRC5; API4; EPR-1; IAP4; survivin variant 3 alpha

For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.